Daptomycin: evaluation of a high-dose treatment strategy

Akins, 2005, Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists, Pharmacotherapy, 25, 1001, 10.1592/phco.2005.25.7.1001 Farrell, 2009, Linezolid surveillance program results for 2008 (LEADER Program for 2008), Diagn Microbiol Infect Dis, 65, 392, 10.1016/j.diagmicrobio.2009.10.011 Soriano, 2008, Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, 46, 193, 10.1086/524667 Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004 Moise, 2009, Safety and clinical outcomes when utilizing high-dose (≥8mg/kg) daptomycin therapy, Ann Pharmacother, 43, 1211, 10.1345/aph.1M085 Tedesco, 2004, Daptomycin, Pharmacotherapy, 24, 41, 10.1592/phco.24.1.41.34802 Dvorchik, 2003, Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects, Antimicrob Agents Chemother, 47, 1318, 10.1128/AAC.47.4.1318-1323.2003 Cubist Pharmaceuticals, 2010 Julian, 2007, Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis, Antimicrob Agents Chemother, 51, 3445, 10.1128/AAC.00559-07 Hidron, 2008, Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis, J Antimicrob Chemother, 61, 1394, 10.1093/jac/dkn105 Lewis, 2005, Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy, Antimicrob Agents Chemother, 49, 1664, 10.1128/AAC.49.4.1664-1665.2005 Benvenuto, 2006, Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers, Antimicrob Agents Chemother, 50, 3245, 10.1128/AAC.00247-06 Katz, 2008, A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria, Int J Clin Pract, 62, 1455, 10.1111/j.1742-1241.2008.01854.x Figueroa, 2009, Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program, Clin Infect Dis, 49, 177, 10.1086/600039 Bassetti, 2010, High-dose daptomycin in documented Staphylococcus aureus infections, Int J Antimicrob Agents, 36, 459, 10.1016/j.ijantimicag.2010.07.011 Cunha, 2008, Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin, Heart Lung, 37, 72, 10.1016/j.hrtlng.2007.04.003 Schutt, 2009, Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin, Ann Pharmacother, 43, 2108, 10.1345/aph.1M324 Cunha, 2006, Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity, Heart Lung, 35, 207, 10.1016/j.hrtlng.2005.09.010 De Rosa, 2009, Early experience with high dosage daptomycin for prosthetic infections, Clin Infect Dis, 49, 1772, 10.1086/648115 Lichterfeld, 2010, High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides, Int J Antimicrob Agents, 35, 96, 10.1016/j.ijantimicag.2009.08.019 Tally, 2000, Development of daptomycin for Gram-positive infections, J Antimicrob Chemother, 46, 523, 10.1093/jac/46.4.523 Carpenter, 2004, Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens, Clin Infect Dis, 38, 994, 10.1086/383472 Eisenstein, 2010, Daptomycin: from the mountain to the clinic with essential help from Francis Tally, MD, Clin Infect Dis, 50, S10, 10.1086/647938 Cha, 2003, Daptomycin dose–effect relationship against resistant Gram-positive organisms, Antimicrob Agents Chemother, 47, 1598, 10.1128/AAC.47.5.1598-1603.2003 Boucher, 2007, Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus, Clin Infect Dis, 45, 601, 10.1086/520655 Sauermann, 2008, Daptomycin: a review 4 years after first approval, Pharmacology, 81, 79, 10.1159/000109868 Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783 Rose, 2008, Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations, J Antimicrob Chemother, 52, 3061, 10.1128/AAC.00102-08 Rose, 2007, Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies, J Antimicrob Chemother, 60, 334, 10.1093/jac/dkm170